IRDS: Predictive 7-gene Signature for Breast Cancer Therapy



    • After surgical removal of breast cancer tumors, adjuvant chemotherapy and radiation therapy have an absolute survival benefit of just 5-10%. Currently approved breast cancer diagnostics do not predict patient responses to these treatment options, despite the capability of such a diagnostic to avoid unnecessarily exposing patients to toxic side effects.
    • From 52 differentially expressed genes, the investigators found 7 genes that successfully predict patient overall survival in response to chemotherapy or radiation therapy. The 7 genes are IFN stimulated and mediate cellular response to DNA damage.
    • The invention is a signature of 7 genes that can be used to predict breast cancer resistance to DNA damage. Lower resistance to DNA damage pinpoints patients that will benefit from chemotherapy and radiation therapy.
    • The gene signature was validated in a retrospective dataset of 295 early stage breast cancer patients (HR=1.2).



    Patients who received adjuvant chemotherapy (green, n=110) and those who did not (orange, n=185) were classified using the clinically approved Mammaprint gene signature (NKI 70) as having a good (NKI70 -) or poor (NKI 70+) prognosis. The poor prognosis patients were further stratified with the invention gene signature (IRDS). IRDS (-) patients have increased sensitivity to chemotherapy, evident in comparing the Kaplan-Meier survival curves of the two treatment groups. 




    • Clear binary results
    • Prevents unnecessary toxic treatments
    • Assesses breast cancer patients not addressed by available tests.
    • Compatible with conventional diagnostic platforms.
    • Greater than 85% sensitivity and specificity
    •  Useful across breast cancer subtypes



    • Precision medicine (Chemotherapy and radiotherapy)
    • Clinical trial enrollment





    • US: 7,892,740



    Reference ID

    Have Questions?

    Michael Hinton

    Contact Michael Hinton, Manager, Technology Marketing, who can provide more detail about this technology, discuss the licensing process, and connect you with the inventor.

    This site uses cookies and other tracking technologies to assist with navigation and your ability to provide feedback, analyze your use of products and services, assist with our promotional and marketing efforts.